Mount Sinai Researchers Define New Biological Hallmarks to Combat Global Liver Cancer Mortality Rates

Mount Sinai researchers publish a landmark review in Cell defining liver cancer hallmarks to improve immunotherapy and precision medicine outcomes for patients.

By: AXL Media

Published: Apr 17, 2026, 7:14 AM EDT

Source: Information for this report was sourced from EurekAlert!

A Scientific Framework for Addressing Global Mortality

Medical researchers led by Dr. Josep M. Llovet and Dr. Daniela Sia have introduced a comprehensive biological blueprint designed to decode the complexities of primary liver cancer. By applying the established Hallmarks of Cancer model to this specific disease, the team has identified the precise mechanisms that allow liver tumors to thrive and resist traditional interventions. This landmark review serves as a critical intervention for a disease that currently accounts for approximately 830,000 deaths every year, positioning the study as a cornerstone for future clinical strategies.

The Evolution of the Hallmarks Concept

The publication coincides with the 25th anniversary of the original cancer hallmarks framework, which was first pioneered by Dr. Douglas Hanahan and Dr. Robert A. Weinberg. According to the research team, adapting this influential model to liver cancer allows for a more granular understanding of how tumors maintain growth signals and evade the human immune system. This historical context provides a foundation for the current study, transforming decades of laboratory data into a functional guide that clinicians can use to navigate the distinct biological landscapes of different tumor types.

Diverging Biological Profiles of HCC and iCCA

The study emphasizes the significant differences between hepatocellular carcinoma and intrahepatic cholangiocarcinoma, the two primary forms of the disease. While the former is characterized by rapid blood vessel formation and immune system suppression, the latter is frequently driven by metabolic alterations. Dr. Sia noted that this specific framework is essential for clinicians to identify the unique vulnerabilities of each tumor type. By distinguishing these profiles, the medical community can move away from generalized treatments toward strategies that address the specific biological signatures of a patient's cancer.